New cancer drug candidate enters first human safety trial
NCT ID NCT06504368
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new drug called DCR-PDL1 in about 32 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and how the body processes it, not to cure the cancer. Participants will receive increasing doses of the drug through an IV to find the safest dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
NEXT Oncology
RECRUITINGIrving, Texas, 75039, United States
-
Next Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a new PET tracer reveal a key cancer target?